AGN 194310pan-RAR antagonist CAS# 229961-45-9 |
- AM580
Catalog No.:BCC5373
CAS No.:102121-60-8
- AGN 195183
Catalog No.:BCC5419
CAS No.:191469-29-1
- Palovarotene
Catalog No.:BCC4185
CAS No.:410528-02-8
- AGN 205728
Catalog No.:BCC5418
CAS No.:859498-05-8
- AGN 196996
Catalog No.:BCC5417
CAS No.:958295-17-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 229961-45-9 | SDF | Download SDF |
| PubChem ID | 9867046 | Appearance | Powder |
| Formula | C28H24O2S | M.Wt | 424.55 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | VTP-194310 | ||
| Solubility | >16.8mg/mL in DMSO | ||
| Chemical Name | 4-[2-[4-(4-ethylphenyl)-2,2-dimethylthiochromen-6-yl]ethynyl]benzoic acid | ||
| SMILES | CCC1=CC=C(C=C1)C2=CC(SC3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C | ||
| Standard InChIKey | LHUPKWKWYWOMSK-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H24O2S/c1-4-19-7-12-22(13-8-19)25-18-28(2,3)31-26-16-11-21(17-24(25)26)6-5-20-9-14-23(15-10-20)27(29)30/h7-18H,4H2,1-3H3,(H,29,30) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with Kd values of 3/2/5 nM for RARα/β/γ respectively.
IC50 value: 3/2/5 nM (Kd for RARα/β/γ) [1][2]
Target: RARs agonist
in vitro: A high affinity pan-RAR antagonist (AGN194310, K(d) for binding to RARs = 2-5 nM) inhibited colony formation (by 50%) by all three lines at 16-34 nM, and led to a transient accumulation of flask-cultured cells in G1 followed by apoptosis. AGN194310 is 12-22 fold more potent than all-trans retinoic acid (ATRA) against cell lines and also more potent in inhibiting the growth of primary prostate carcinoma cells [2].
in vivo: The administration of all-trans retinoic acid to VAD mice resulted in a transient reduction in NF-kappaB activity and, conversely, a single dose of the RAR-pan-antagonist, AGN 194310, administered to control mice, led to a marked, transient induction of whole-body luminescence [3]. Mice were treated with AGN194310, a synthetic retinoid that antagonises the physiological function of the three RAR isotypes (alpha, beta, gamma) but does not interact with RXRs. Analyses of the granulocytic lineage using Gr-1, c-Kit and CD11b antibodies, demonstrated that granulocyte numbers were strikingly increased across haemopoietic compartments in all AGN194310-treated mice. A significant increase in the frequency of progenitor cells containing granulocytes was observed in the bone marrow of mice following treatment with AGN194310 [4]. References: | |||||
AGN 194310 Dilution Calculator
AGN 194310 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3554 mL | 11.7772 mL | 23.5544 mL | 47.1087 mL | 58.8859 mL |
| 5 mM | 0.4711 mL | 2.3554 mL | 4.7109 mL | 9.4217 mL | 11.7772 mL |
| 10 mM | 0.2355 mL | 1.1777 mL | 2.3554 mL | 4.7109 mL | 5.8886 mL |
| 50 mM | 0.0471 mL | 0.2355 mL | 0.4711 mL | 0.9422 mL | 1.1777 mL |
| 100 mM | 0.0236 mL | 0.1178 mL | 0.2355 mL | 0.4711 mL | 0.5889 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AGN 194310 is a pan-antagonist of retinoic acid receptors (RARs) with Kd values of 3nM, 2nM and 5nM for RAR α, RARβ and RARγ, respectively [1].
AGN 194310 has been reported to bind to RARs with equal and high Kd values of 3, 2 and 5nM for RAR α, RARβ and RARγ, respectively, by in vitro binding experiments. In addition, AGN 194310 has been revealed to potently inhibit the colony formation by ITS+-grown cell lines with IC50 values of 16 ± 5nM for LNCaP cells; 18 ± 6nM for PC3 cells; and 34 ± 7nM for DU-145 cells. Apart from these, because of binding to and mediating the effects via RARs, AGN 194310 has been demonstrated to inhibit agonist-induced (TTNPB) differentiation of HL60 cells. AGN 194310 has also shown the accumulation of cell in G1 and the function of induced apoptosis [1].
References:
[1] Hammond LA1, Van Krinks CH, Durham J, Tomkins SE, Burnett RD, Jones EL, Chandraratna RA, Brown G. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells.Br J Cancer. 2001 Aug 3; 85(3):453-62.
- GW9662
Catalog No.:BCC2260
CAS No.:22978-25-2
- Abn-CBD
Catalog No.:BCC7011
CAS No.:22972-55-0
- Desmethoxycentaureidin
Catalog No.:BCN5077
CAS No.:22934-99-2
- Neferine
Catalog No.:BCN6338
CAS No.:2292-16-2
- Ginkgolic acid C15:1
Catalog No.:BCN2307
CAS No.:22910-60-7
- R 892
Catalog No.:BCC5992
CAS No.:229030-05-1
- TAK-779
Catalog No.:BCC4137
CAS No.:229005-80-5
- 4-Amino-3,5-dichloropyridine
Catalog No.:BCC8679
CAS No.:22889-78-7
- Silymarin
Catalog No.:BCN6299
CAS No.:22888-70-6
- Famprofazone
Catalog No.:BCC3779
CAS No.:22881-35-2
- 6-Acetonyldihydrochelerythrine
Catalog No.:BCN5076
CAS No.:22864-92-2
- Anisomycin
Catalog No.:BCC7007
CAS No.:22862-76-6
- Atazanavir sulfate (BMS-232632-05)
Catalog No.:BCC2114
CAS No.:229975-97-7
- MPTP hydrochloride
Catalog No.:BCC1778
CAS No.:23007-85-4
- Neoglycyrol
Catalog No.:BCN2907
CAS No.:23013-84-5
- Physalin A
Catalog No.:BCN7920
CAS No.:23027-91-0
- Apelin-36 (rat, mouse)
Catalog No.:BCC5911
CAS No.:230299-95-3
- Terbutaline Sulfate
Catalog No.:BCC4320
CAS No.:23031-32-5
- Z-β-Ala-OH
Catalog No.:BCC3058
CAS No.:2304-94-1
- Z-Asn-OH
Catalog No.:BCC2794
CAS No.:2304-96-3
- Z-Arg(NO2)-OH
Catalog No.:BCC3063
CAS No.:2304-98-5
- Ajugasterone C
Catalog No.:BCN2757
CAS No.:23044-80-6
- Lofepramine
Catalog No.:BCC7402
CAS No.:23047-25-8
- Dihydroconiferyl alcohol
Catalog No.:BCN7047
CAS No.:2305-13-7
Complexes of DNA bases and Watson-Crick base pairs interaction with neutral silver Agn (n = 8, 10, 12) clusters: a DFT and TDDFT study.[Pubmed:28325114]
J Biomol Struct Dyn. 2018 Mar;36(4):1050-1062.
We study the binding of the neutral Agn (n = 8, 10, 12) to the DNA base-adenine (A), guanine (G) and Watson-Crick -adenine-thymine, guanine-cytosine pairs. Geometries of complexes were optimized at the DFT level using the hybrid B3LYP functional. LANL2DZ effective core potential was used for silver and 6-31 + G(**) was used for all other atoms. NBO charges were analyzed using the Natural population analysis. The absorption properties of Agn-A,G/WC complexes were also studied using time-dependent density functional theory. The absorption spectra for these complexes show wavelength in the visible region. It was revealed that silver clusters interact more strongly with WC pairs than with isolated DNA complexes. Furthermore, it was found that the electronic charge transferred from silver to isolated DNA clusters are less than the electronic charge transferred from silver to the Agn-WC complexes. The vertical ionization potential, vertical electron affinity, hardness, and electrophilicity index of Agn-DNA/WC complexes have also been discussed.
Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression.[Pubmed:27605402]
Phytother Res. 2016 Dec;30(12):2020-2026.
Angelica gigas Nakai (AGN, Korean Dang-gui) is traditionally used for the treatment of various diseases including cancer. Here, we investigated multidrug-resistant phenotype-reversal activities of AGN and its compounds (decursin, ferulic acid, and nodakenin) in doxorubicin-resistant NCI/ADR-RES ovarian cancer cells. Our results showed that a combination of doxorubicin with either AGN or decursin inhibited a proliferation of NCI/ADR-RES cells. These combinations increased the number of cells at sub-G1 phase when cells were stained with Annexin V-fluorescein isothiocyanate. We also found that these combinations activated caspase-9, caspase-8, and caspase-3 and increased cleaved PARP level. Moreover, an inhibition of P-glycoprotein expression by either AGN or decursin resulted in a reduction of its activity in NCI/ADR-RES cells. Therefore, our data demonstrate that decursin in AGN inhibits doxorubicin-resistant ovarian cancer cell proliferation and induces apoptosis in the presence of doxorubicin via blocking P-glycoprotein expression. Therefore, AGN would be a potentially novel treatment option for multidrug-resistant tumors by sensitizing to anticancer agents. Copyright (c) 2016 John Wiley & Sons, Ltd.
Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds.[Pubmed:22583405]
Anticancer Agents Med Chem. 2012 Dec;12(10):1239-54.
Korean Angelica gigas Nakai (AGN) is a major medicinal herb used in Asian countries such as Korea and China. Traditionally, its dried root has been used to treat anemia, pain, infection and articular rheumatism in Korea, most often through boiling in water to prepare the dosage forms. The pyranocoumarin compound decursin and its isomer decursinol angelate (DA) are the major chemical components in the alcoholic extracts of the root of AGN. The in vitro anti-tumor activities of decursin and/or DA against prostate cancer, lung cancer, breast cancer, colon cancer, bladder cancer, sarcoma, myeloma and leukemia have been increasingly reported in the past decade whereas the in vivo efficacy in mouse models was established only for a few organ sites. Preliminary pharmacokinetic studies by us and others in rodent models indicated that decursinol (DOH), which has much less in vitro direct anticancer activities by itself, is the major and rapid in vivo hydrolysis metabolite of both decursin and DA. Besides decursin, DA and DOH, other chemical components in AGN such as polysaccharides and polyacetylenes have been reported to exert anti-cancer and anti-inflammation activities as well. We systematically reviewed the published literature on the anti-cancer and other bio-activities effects of AGN extract and decursin, DA and DOH, as well as other chemicals identified from AGN. Although a number of areas are identified that merit further investigation, one critical need is first-in-human studies of the pharmacokinetics of decursin/DA to determine whether humans differ from rodents in absorption and metabolism of these compounds.
Usefulness of Chromogenic CromoCen(R) AGN agar medium for the identification of the genus Aeromonas: Assessment of faecal samples.[Pubmed:22561188]
J Microbiol Methods. 2012 Aug;90(2):100-4.
Selective screening media for the detection and identification of Aeromonas strains are needed to guide primary isolation procedures in the clinical laboratory. This study compared the selective CromoCen(R) AGN chromogenic agar medium for the detection and identification of Aeromonas strains that were isolated from various samples against the conventional selective agar media that are commonly used for the isolation of this organism in food, environmental and clinical samples. The Miles and Misra and ecometric methods were used to evaluate the microbiological performance of CromoCen(R) AGN chromogenic agar medium, which was shown to be satisfactory. A total of 14 reference Aeromonas strains, 44 wild strains and 106 clinical stool specimens were examined using both non-chromogenic selective agars that are commonly used for Aeromonas isolation and CromoCen(R) AGN agar. The latter exhibited 94.73% sensitivity and 100% specificity for the various samples. On CromoCen(R) AGN agar medium, Aeromonas formed colonies with light green, greenish and salmon pigments with or without a surrounding wide transparent zone (halo) of 2-3mm in diameter around the entire border. This medium is recommended for the isolation and potential identification of the Aeromonas genus.
